# Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
Canonical URL: https://biopharmsignal.com/news/KALV/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals
Ticker: KALV
Company: KalVista Pharmaceuticals, Inc.
Source: KalVista Pharmaceuticals, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.kalvista.com
## Summary

Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases PARMA, Italy & FRAMINGHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2026-- Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition

## Article Body
Positioned to Expand Patient Access and Accelerate Impact in Rare Diseases PARMA, Italy & FRAMINGHAM, Mass. --(BUSINESS WIRE)--Jun. 11, 2026-- Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition
## Recent Company News
- 2026-06-25 13:46 EST — [Chiesi Group Completes Acquisition of KalVista Pharmaceuticals](https://biopharmsignal.com/news/KALV/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-the-burden-of-injectable-on-demand-treatment-in-young-children-with-hereditary-angioedema) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-at-upcoming-investor-conferences) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-high-patient-satisfaction-and-evolving-treatment-trends-with-ekterlyr-sebetralstat) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026) — Source: KalVista Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)